VivoSeq
Other

Low Risk

0

Pipeline Programs↗

3

Active Trials↗

2

Companies Involved↗

Low Risk is an early-stage landscape with 0 programs across 2 companies. The most active players are Novartis, Minovia Therapeutics Ltd..

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalM

Minovia Therapeutics Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Completed4 · 57%
Active, not recruiting2 · 29%
Recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

A Study to Evaluate the MNV-201 in Patients With Low Risk MDS
Recruiting·MMinovia Therapeutics Ltd.·Phase 1·NCT06465160·15 enrolled
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma
Active, not recruiting·UUniversity of Arkansas·Phase 3·NCT00734877·382 enrolled
Decision Making in Men With Early Stage Prostate Cancer Patients and Partners/Close Allies
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·N/A·NCT01877070·541 enrolled
Biological Predictive Factors of Response to ESA in Low Risk MDS Patients
Completed·AAssociation pour la recherche sur les Affections Malignes en Immunologie Sanguine·Phase 4·NCT03598582·70 enrolled
Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations
Completed·Novartis logoNovartis·Phase 4·NCT02418468·24 enrolled
Itacitinib for Low Risk GVHD
Completed·—·Phase 2·NCT03846479·70 enrolled
Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients
Completed·SSheba Medical Center·Phase 2·NCT02477631·19 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)